MS On Biocon
OW, TP Rs 350
Launched Biosimilar Trastuzumab In US As Per Terms Of Its Settlement
It’s 2nd Biosimilar Launch & Each Pdt Was An Early Entrant In Mkt
Importantly, Management Has Reiterated Its $1 Bn Biosimilar Sales Tgt For F22
Feedback
BIOCON 
Reputation: 13,324 • Dec 3, 2019 1:43 PM
Vote
Comment
Share